» Articles » PMID: 38099995

Blood Pressure, Hypertension, and Antihypertensive Medication Use and Risk of Total and Fatal Prostate Cancer in Black and White Men in the Atherosclerosis Risk in Communities (ARIC) Study

Overview
Date 2023 Dec 15
PMID 38099995
Authors
Affiliations
Soon will be listed here.
Abstract

Black men are disproportionately burdened by hypertension and prostate cancer (PCa), and some cohorts suggest hypertension is associated with increased PCa risk. We investigated the association of hypertension and antihypertensive use with total (N = 889; 290 Black, 599 White) and fatal (N = 127; 42 Black, 85 White) PCa risk in 6658 (1578 Black, 5080 White) men in the Atherosclerosis Risk in Communities study. In adjusted Cox models, time-updated untreated stage 1 hypertension (systolic/diastolic blood pressure 130-139/80-89 mmHg) was associated with a higher risk of fatal PCa compared to untreated normal blood pressure (hazard ratio (HR) = 1.95; 95% confidence interval (CI) = 1.03-3.70). Compared to untreated normal/elevated blood pressure (combined given few events in those with untreated normal blood pressure), the association was significant in Black (HR = 3.35; 95% CI = 1.27-8.83), but not White (HR = 1.21; 95% CI = 0.58-2.55) men. Ever antihypertensive use was associated with a lower risk of fatal PCa compared to never use (HR = 0.52; 95% CI = 0.31-0.87), including short-term (< 10 years) and long-term (10 years) use (p-trend = 0.02) with similar inverse associations in Black and White men. Hypertension and antihypertensive use were not significantly associated with total PCa. The positive association of untreated stage 1 hypertension and fatal PCa warrants additional confirmation, especially in Black men, and characterization of the underlying mechanism.

Citing Articles

Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders.

Pagoni M, Zogopoulos V, Kontogiannis S, Tsolakou A, Zoumpourlis V, Tsangaris G Cancer Genomics Proteomics. 2025; 22(2):285-305.

PMID: 39993800 PMC: 11880924. DOI: 10.21873/cgp.20502.

References
1.
Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

2.
Gu A, Yue Y, Desai R, Argulian E . Racial and Ethnic Differences in Antihypertensive Medication Use and Blood Pressure Control Among US Adults With Hypertension: The National Health and Nutrition Examination Survey, 2003 to 2012. Circ Cardiovasc Qual Outcomes. 2017; 10(1). DOI: 10.1161/CIRCOUTCOMES.116.003166. View

3.
Liang Z, Xie B, Li J, Wang X, Wang S, Meng S . Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016; 6:31358. PMC: 4980763. DOI: 10.1038/srep31358. View

4.
Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez D, Ntzani E . Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019; 9(1):8565. PMC: 6561976. DOI: 10.1038/s41598-019-45014-4. View

5.
Dickerman B, Torfadottir J, Valdimarsdottir U, Wilson K, Steingrimsdottir L, Aspelund T . Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer. 2017; 142(6):1166-1173. PMC: 5773388. DOI: 10.1002/ijc.31142. View